The company tops Q1 profit estimates on robust demand for cystic fibrosis treatments

Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs. Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter.

Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation.